Correspondence - Form CORRESP

September 7, 2022

Via EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn: Joshua Gorsky

Re:	Humacyte, Inc.
Registration Statement Filed on Form S-3 (the "Registration Statement")
File No. 333-267225

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Humacyte, Inc. (the "Company") hereby respectfully requests that the effective date for the above-referenced Registration Statement be accelerated to 4:00 p.m., Eastern Time, on September 9, 2022, or as soon as practicable thereafter.

Please contact Kerry S. Burke of Covington & Burling LLP at (202) 662-5297 or [email protected] with any questions you may have regarding this request. In addition, please notify Ms. Burke by telephone when this request for acceleration has been granted.

Respectfully,
Humacyte, Inc.
By:	/s/ Dale A. Sander
Name:	Dale A. Sander
Title:	Chief Financial Officer

cc: Kerry S. Burke, Covington & Burling LLP

Brian K. Rosenzweig, Covington & Burling LLP